Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

FX. Mahon, M. Pfirrmann, S. Dulucq, A. Hochhaus, P. Panayiotidis, A. Almeida, J. Mayer, H. Hjorth-Hansen, JJWM. Janssen, S. Mustjoki, J. Martinez-Lopez, H. Vestergaard, H. Ehrencrona, K. Machová Poláková, U. Olsson-Strömberg, G. Ossenkoppele, MG....

. 2024 ; 42 (16) : 1875-1880. [pub] 20240312

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013754

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Bergonié Cancer Institute INSERM UMR1312 Inserm University of Bordeaux Bordeaux France

Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf Aachen Germany

Centre Léon Bérard Lyon France

Department of Genetics and Pathology Laboratory Medicine Region Skåne Lund Sweden

Department of Haematology Odense University Hospital Odense Denmark

Department of Haematology Oncology and Radiation Physics Skåne University Hospital Lund Sweden

Department of Hematology Amsterdam UMC Location VUMC Amsterdam the Netherlands

Department of Hematology and Oncology University Hospital Mannheim Heidelberg University Mannheim Germany

Department of Hematology Centre Hospitalier de Versailles INSERM UMR 1184 Université Versailles Paris Saclay Le Chesnay France

Department of Hematology Oncology and Immunology Philipps University Marburg Faculty of Medicine Marburg Germany

Department of Hematology Oncology Hemostaseology and Stem Cell Transplantation Medical Faculty RWTH Aachen University Aachen Germany

Department of Internal Medicine Hematology and Oncology Masaryk University and University Hospital Brno Brno Czech Republic

Department of Medical Science and Division of Hematology University Hospital Uppsala Sweden

Division of Clinical Genetics Department of Laboratory Medicine Lund University Lund Sweden

Faculdade de Medicina Universidade Católica Portuguesa Lisbon Portugal

Groupe Fi LMC Centre Léon Bérard Lyon France

Hématologie Biologique and EA 7453 CHELTER CHU Estaing and Université Clermont Auvergne Clermont Ferrand France

Hematology Department Institut Bergonié Bordeaux France

Hematology Research Unit Helsinki and Translational Immunology Research Program University of Helsinki and Helsinki University Comprehensive Cancer Center Helsinki Finland

Hospital 12 de Octubre CNIO i 12 Department of Medicine Univ Complutense Madrid Spain

ICAN Digital Precision Cancer Medicine Flagship Helsinki Finland

Innere Medizin 3 Diakonie Klinikum Schwäbisch Hall Germany

Institut für Medizinische Informationsverarbeitung Biometrie und Epidemiologie Medizinische Fakultät LMU München München Germany

Institute of Hematology and Blood Transfusion Prague Czech Republic

Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany

Laboratory of Hematology University Hospital of Bordeaux Hôpital Haut Lévêque Pessac France

Laikon General Hospital National and Kapodistrian University of Athens Athens Greece

Onkologische Schwerpunktpraxis Heilbronn Heilbronn Germany

Service d'Hématologie Adulte and INSERM UMR 1160 Hôpital Saint Louis Paris France

St Olavs Hospital HF Trondheim Norway

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013754
003      
CZ-PrNML
005      
20240905133442.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.23.01647 $2 doi
035    __
$a (PubMed)38471049
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mahon, Francois-Xavier $u Bergonié Cancer Institute, INSERM UMR1312 Inserm, University of Bordeaux, Bordeaux, France $1 https://orcid.org/0000000315456775
245    10
$a European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission / $c FX. Mahon, M. Pfirrmann, S. Dulucq, A. Hochhaus, P. Panayiotidis, A. Almeida, J. Mayer, H. Hjorth-Hansen, JJWM. Janssen, S. Mustjoki, J. Martinez-Lopez, H. Vestergaard, H. Ehrencrona, K. Machová Poláková, U. Olsson-Strömberg, G. Ossenkoppele, MG. Berger, G. Etienne, J. Dengler, TH. Brümmendorf, A. Burchert, D. Réa, P. Rousselot, FE. Nicolini, WK. Hofmann, J. Richter, S. Saussele, EURO-SKI Investigators, Investigators
520    9_
$a Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.
650    _2
$a lidé $7 D006801
650    12
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464
650    12
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    12
$a indukce remise $7 D012074
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a prognóza $7 D011379
650    _2
$a imatinib mesylát $x terapeutické užití $7 D000068877
650    _2
$a bcr-abl fúzní proteiny $x genetika $x antagonisté a inhibitory $7 D016044
650    _2
$a pyrimidiny $x terapeutické užití $7 D011743
650    _2
$a mladý dospělý $7 D055815
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory tyrosinkinasy $7 D000092004
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Pfirrmann, Markus $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, LMU München, München, Germany $1 https://orcid.org/0000000289480690
700    1_
$a Dulucq, Stéphanie $u Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac, France $u Groupe Fi-LMC, Centre Léon Bérard, Lyon, France $1 https://orcid.org/0000000327287243
700    1_
$a Hochhaus, Andreas $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany $1 https://orcid.org/0000000306260834
700    1_
$a Panayiotidis, Panayiotis $u Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Almeida, Antonio $u Faculdade de Medicina, Universidade Católica Portuguesa, Lisbon, Portugal $1 https://orcid.org/0000000343610928
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000305679887 $7 nlk20000083651
700    1_
$a Hjorth-Hansen, Henrik $u St Olavs Hospital HF, Trondheim, Norway $1 https://orcid.org/0000000226705696
700    1_
$a Janssen, Jeroen J W M $u Department of Hematology, Amsterdam UMC, Location VUMC, Amsterdam, the Netherlands
700    1_
$a Mustjoki, Satu $u Hematology Research Unit Helsinki and Translational Immunology Research Program, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland $u ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland $1 https://orcid.org/0000000208168241
700    1_
$a Martinez-Lopez, Joaquin $u Hospital 12 de Octubre, CNIO, i+12, Department of Medicine Univ. Complutense, Madrid, Spain $1 https://orcid.org/0000000179080063
700    1_
$a Vestergaard, Hanne $u Department of Haematology, Odense University Hospital, Odense, Denmark
700    1_
$a Ehrencrona, Hans $u Department of Genetics and Pathology, Laboratory Medicine, Region Skåne, Lund, Sweden $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden $1 https://orcid.org/0000000255893622
700    1_
$a Machová Poláková, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Olsson-Strömberg, Ulla $u Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden
700    1_
$a Ossenkoppele, Gert $u Department of Hematology, Amsterdam UMC, Location VUMC, Amsterdam, the Netherlands
700    1_
$a Berger, Marc G $u Hématologie Biologique and EA 7453 CHELTER, CHU Estaing and Université Clermont Auvergne, Clermont-Ferrand, France $1 https://orcid.org/0000000318580587
700    1_
$a Etienne, Gabriel $u Groupe Fi-LMC, Centre Léon Bérard, Lyon, France $u Hematology Department, Institut Bergonié, Bordeaux, France $1 https://orcid.org/0000000176004954
700    1_
$a Dengler, Jolanta $u Onkologische Schwerpunktpraxis Heilbronn, Heilbronn, Germany $u Innere Medizin III, Diakonie-Klinikum, Schwäbisch Hall, Germany
700    1_
$a Brümmendorf, Tim H $u Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany $u Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany $1 https://orcid.org/0000000296773723
700    1_
$a Burchert, Andreas $u Department of Hematology, Oncology and Immunology, Philipps University Marburg Faculty of Medicine, Marburg, Germany $1 https://orcid.org/0000000284118844
700    1_
$a Réa, Delphine $u Service d'Hématologie Adulte and INSERM UMR-1160, Hôpital Saint-Louis, Paris, France $1 https://orcid.org/0000000153797461
700    1_
$a Rousselot, Philippe $u Department of Hematology, Centre Hospitalier de Versailles, INSERM UMR 1184, Université Versailles Paris Saclay, Le Chesnay, France
700    1_
$a Nicolini, Franck E $u Centre Léon Bérard, Lyon, France
700    1_
$a Hofmann, Wolf-Karsten $u Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany
700    1_
$a Richter, Johan $u Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
700    1_
$a Saussele, Susanne $u Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany $1 https://orcid.org/0000000303575785
710    2_
$a EURO-SKI Investigators
710    2_
$a Investigators
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 42, č. 16 (2024), s. 1875-1880
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38471049 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133435 $b ABA008
999    __
$a ok $b bmc $g 2143515 $s 1225620
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 16 $d 1875-1880 $e 20240312 $i 1527-7755 $m Journal of clinical oncology $n J Clin Oncol $x MED00002596
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace